KRAS mutation in patients with metastatic colorectal cancer does not preclude benefit from oxaliplatin‑ or irinotecan‑based treatment
Soeda, Hiroshi, Shimodaira, Hideki, Watanabe, Mika, Suzuki, Takao, Gamo, Makio, Takahashi, Masanobu, Komine, Keigo, Kato, Shunsuke, Ishioka, ChikashiLangue:
english
Journal:
Molecular and Clinical Oncology
DOI:
10.3892/mco.2014.254
Date:
February, 2014
Fichier:
PDF, 537 KB
english, 2014
File converter
Plus de résultats de recherche
More benefits 
